Table 2.

Current stem cell therapies for retinal degenerations

Clinical disease	Intervention	Phase	Route	Sponsor	Trial ID
Macular degenerative disease	hESC-RPE cells	I/II	SR suspension	AIRM	NCT03167203
AMD	Autologous iPSC-derived RPE on PGLA	I/II	SR-sheet	NEI	NCT04339764
RP	UMSC	II	Sub Tenon’s space	JBRCS	NCT04763369
AMD/Stargardt disease	injection of hESC-RPE in suspension/substrate	I/II	SR suspension vs. sheet	Federal University of São Paulo	NCT02903576
RP	hESC-RPE cells	I	SR suspension	Qi Zhou	NCT03944239
Stargardt	hESC-RPE	I/II	SR suspension	AIRM	NCT02941991
RP	Human retinal progenitor cells	II	IVT suspension	jCyte, Inc	NCT04604899
Dry AMD	hESC-RPE on CPCB-RPE1	I/II	SR sheet	RPT	NCT02590692
Stargardt	MA09-hRPE hESC-RPE cells	I/II	SR suspension	AIRM	NCT01469832
RP	Wharton’s jelly derived MSC	III	Deep sub Tenon’s	Ankara Universitesi Teknokent	NCT04224207
AMD, RP	CD34+bone marrow stem cells	I	IVT	UCD	NCT01736059
Stargardt	MA09-hRPE	I/II	SR	AIRM	NCT01345006
Dry AMD	MA09-hRPE	I/II	SR	AIRM	NCT01344993
RP	Human Retinal progenitor cells	I/II	SR	ReNeuron Limited	NCT02464436
Dry AMD	Opregen hESC-RPE cells	I/II	SR suspension	Lineage Cell Therapeutics, Inc.	NCT02286089
RP	human neural progenitor cells (CNS10-NPC)	I	SR	Cedars-Sinai Medical Center	NCT04284293

Source: www.clinicaltrials.gov AMD- Age-Related Macular Degeneration, RP- Retinitis Pigmentosa, hESC-RPE- Human Embryonic Stem Cells- Retinal Pigment Epithelium, iPSC- Induced Pluripotent Stem Cells, PGLA- poly lactic-co-glycolic acid, UMSC-Umbilical Cord Derived Mesenchymal Stem Cells, CPCB-RPE1- California Project to Cure Blindness-Retinal Pigment Epithelium1, SR- subretinal, IVT- Intravitreal, AIRM-Astellas Institute for Regenerative Medicine, JBRCS- Jinnah Burn and Reconstructive Surgery Centre, Lahore, NEI- National Eye Institute, RPT-Regenerative Patch Technologies, SR- Subretinal, UCD- University of California, Davis